Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update
11. August 2023 07:45 ET
|
Decibel Therapeutics, Inc.
- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023...
Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference
02. Juni 2023 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
01. Juni 2023 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit
17. Mai 2023 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
15. Mai 2023 07:45 ET
|
Decibel Therapeutics, Inc.
- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to...
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO
12. Mai 2023 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
10. Mai 2023 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
30. März 2023 07:00 ET
|
Decibel Therapeutics, Inc.
- Decibel intends to initiate a Phase 1/2 clinical trial of DB-OTO in patients with congenital hearing loss caused my mutations of the otoferlin gene in the first half of 2023 - - There are currently...
Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
28. März 2023 16:30 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 28, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors
21. März 2023 07:00 ET
|
Decibel Therapeutics, Inc.
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...